Research & development expenses as a percentage of revenues expanded 590 bps year over year to 28.2%.Non-GAAP operating margin came in at 29.3% compared with 42.9% reported in the year-ago quarter on account of decline in gross margin and higher expenses.Balance Sheet & Cash FlowAs of Mar 31, 2020, cash and short-term investments of $718 million (the United States comprised 60%) compared with $872.4 million (the United States comprised 72%) as of Dec 31, 2019.As of Mar 31, 2020, the company has an unsecured term loan with an outstanding principal balance of $425 million.Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>